Incorrect again. Cash is $11.6m. Biotech Dollars = 1 x 1.43 for refunds from the Govt for R&D. Puts OSL @ about $16m in effective dollars. Trial is about $2m. Mkt cap is very low and as more goals are kicked, patients recruited, treated, results, this will tighten up.
Sure a CR will happen at some stage, but will be at higher prices. Regal came in at 22cps and management and Board perf shares are exercisable @ 22cps. As insto buying soaks up loose stock, they know they will have to be in to be part of an CR.
This has been to 27cps in a worse state than it is today and whilst agree, sentiment is now neutral as said by Oli, it should improve as more items are ticked off. To tighten this up would not take a great deal and if it does not pop, a t/over could certainly be in the wings, maybe even SRX, who could get a new Chairman in Chris Roberts!
OSL Price at posting:
9.2¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)